Lineage Cell Therapeutics, Inc. Quarterly Return On Equity in % from Q1 2012 to Q2 2024

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
Lineage Cell Therapeutics, Inc. quarterly/annual Return On Equity history and growth rate from Q1 2012 to Q2 2024.
  • Lineage Cell Therapeutics, Inc. Return On Equity for the quarter ending June 30, 2024 was -36.3 %, a 19.4% decline year-over-year.
  • Lineage Cell Therapeutics, Inc. annual Return On Equity for 2023 was -32 %, a 3.85% increase from 2022.
  • Lineage Cell Therapeutics, Inc. annual Return On Equity for 2022 was -33.2 %, a 13% increase from 2021.
  • Lineage Cell Therapeutics, Inc. annual Return On Equity for 2021 was -38.2 %, a 79.2% decline from 2020.
Return On Equity, Quarterly (%)
Return On Equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Start Date End Date
Q2 2024 -36.3 -5.89 -19.4% Apr 1, 2024 Jun 30, 2024
Q1 2024 -34.9 -3.52 -11.2% Jan 1, 2024 Mar 31, 2024
Q4 2023 -32 +1.28 +3.85% Oct 1, 2023 Dec 31, 2023
Q3 2023 -33.1 +25.3 +43.3% Jul 1, 2023 Sep 30, 2023
Q2 2023 -30.4 +23.3 +43.4% Apr 1, 2023 Jun 30, 2023
Q1 2023 -31.4 +15 +32.4% Jan 1, 2023 Mar 31, 2023
Q4 2022 -33.2 +4.95 +13% Oct 1, 2022 Dec 31, 2022
Q3 2022 -58.4 -47.8 -453% Jul 1, 2022 Sep 30, 2022
Q2 2022 -53.7 -42.5 -379% Apr 1, 2022 Jun 30, 2022
Q1 2022 -46.5 -32.8 -240% Jan 1, 2022 Mar 31, 2022
Q4 2021 -38.2 -16.9 -79.2% Oct 1, 2021 Dec 31, 2021
Q3 2021 -10.6 +16.4 +60.8% Jul 1, 2021 Sep 30, 2021
Q2 2021 -11.2 +22.3 +66.5% Apr 1, 2021 Jun 30, 2021
Q1 2021 -13.7 +37.6 +73.3% Jan 1, 2021 Mar 31, 2021
Q4 2020 -21.3 -12.3 -136% Oct 1, 2020 Dec 31, 2020
Q3 2020 -26.9 +14.8 +35.5% Jul 1, 2020 Sep 30, 2020
Q2 2020 -33.5 -55.9 -249% Apr 1, 2020 Jun 30, 2020
Q1 2020 -51.3 -94.4 -219% Jan 1, 2020 Mar 31, 2020
Q4 2019 -9.01 +30.2 +77% Oct 1, 2019 Dec 31, 2019
Q3 2019 -41.7 +12.3 +22.7% Jul 1, 2019 Sep 30, 2019
Q2 2019 22.4 +109 Apr 1, 2019 Jun 30, 2019
Q1 2019 43.1 +124 Jan 1, 2019 Mar 31, 2019
Q4 2018 -39.2 -28.4 -264% Oct 1, 2018 Dec 31, 2018
Q3 2018 -54 -80.5 -303% Jul 1, 2018 Sep 30, 2018
Q2 2018 -86.4 -127 -315% Apr 1, 2018 Jun 30, 2018
Q1 2018 -81.2 -154 -212% Jan 1, 2018 Mar 31, 2018
Q4 2017 -10.8 -42.8 -134% Oct 1, 2017 Dec 31, 2017
Q3 2017 26.6 -0.85 -3.1% Jul 1, 2017 Sep 30, 2017
Q2 2017 40.3 +67.3 Apr 1, 2017 Jun 30, 2017
Q1 2017 72.7 +155 Jan 1, 2017 Mar 31, 2017
Q4 2016 32.1 +104 Oct 1, 2016 Dec 31, 2016
Q3 2016 27.4 +99 Jul 1, 2016 Sep 30, 2016
Q2 2016 -27.1 +42 +60.8% Apr 1, 2016 Jun 30, 2016
Q1 2016 -82.4 -7.48 -9.99% Jan 1, 2016 Mar 31, 2016
Q4 2015 -72.3 +2.97 +3.94% Oct 1, 2015 Dec 31, 2015
Q3 2015 -71.6 +33.5 +31.9% Jul 1, 2015 Sep 30, 2015
Q2 2015 -69.1 +46.8 +40.4% Apr 1, 2015 Jun 30, 2015
Q1 2015 -74.9 +45.2 +37.6% Jan 1, 2015 Mar 31, 2015
Q4 2014 -75.3 +57.5 +43.3% Oct 2, 2014 Dec 31, 2014
Q3 2014 -105 +1.1 +1.04% Jul 1, 2014 Sep 30, 2014
Q2 2014 -116 -26.9 -30.2% Apr 1, 2014 Jun 30, 2014
Q1 2014 -120 -37.9 -46.2% Jan 1, 2014 Mar 31, 2014
Q4 2013 -133 -63.5 -91.6% Sep 29, 2013 Dec 31, 2013
Q3 2013 -106 -47.9 -82.1% Jul 1, 2013 Sep 30, 2013
Q2 2013 -89 -40.3 -82.7% Apr 1, 2013 Jun 30, 2013
Q1 2013 -82.1 -40.2 -96% Jan 1, 2013 Mar 31, 2013
Q4 2012 -69.3 Oct 1, 2012 Dec 31, 2012
Q3 2012 -58.3 Jul 1, 2012 Sep 30, 2012
Q2 2012 -48.7 Apr 1, 2012 Jun 30, 2012
Q1 2012 -41.9 Jan 1, 2012 Mar 31, 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.